Abbott Laboratories Website

Abbott Laboratories

NYSE-ABT

Basic

  • Market Cap

    $183.88B

  • EV

    $192.7B

  • Shares Out

    1,735.18M

  • Revenue

    $40.33B

  • Employees

    114,000

Margins

  • Gross

    55.28%

  • EBITDA

    25.65%

  • Operating

    17.6%

  • Pre-Tax

    16.21%

  • Net

    13.96%

  • FCF

    12.61%

Returns (5Yr Avg)

  • ROA

    7.6%

  • ROTA

    28.16%

  • ROE

    15.96%

  • ROCE

    11.92%

  • ROIC

    11.23%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $126.33

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    $7,279M

  • Net Debt

    $8,594M

  • Debt/Equity

    0.41

  • EBIT/Interest

    10.99

Growth (CAGR)

  • Rev 3Yr

    2.6%

  • Rev 5Yr

    5.59%

  • Rev 10Yr

    7.8%

  • Dil EPS 3Yr

    0.19%

  • Dil EPS 5Yr

    16.84%

  • Dil EPS 10Yr

    7.66%

  • Rev Fwd 2Yr

    5.63%

  • EBITDA Fwd 2Yr

    7%

  • EPS Fwd 2Yr

    7.43%

  • EPS LT Growth Est

    6.5%

Dividends

  • Yield

    —

  • Payout

    65.76%

  • DPS

    $2.12

  • DPS Growth 3Yr

    9.38%

  • DPS Growth 5Yr

    12.05%

  • DPS Growth 10Yr

    11.4%

  • DPS Growth Fwd 2Yr

    5.49%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Metric
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
LTM

Total Revenues

31,904

34,608

43,075

43,653

40,109

40,326

Total Revenues % Chg.

4.3%

8.5%

24.5%

1.3%

-8.1%

-2.8%

Cost of Goods Sold, Total

13,231

15,003

18,080

19,083

17,919

18,034

Gross Profit

18,673

19,605

24,995

24,570

22,190

22,292

Selling General & Admin Expenses, Total

9,540

9,591

11,006

10,703

10,385

10,597

R&D Expenses

2,440

2,420

2,738

2,741

2,619

2,651

Amortization of Goodwill and Intangible Assets

1,936

2,132

2,047

2,013

1,966

1,947

Other Operating Expenses, Total

13,916

14,143

15,791

15,457

14,970

15,195

Operating Income

4,757

5,462

9,204

9,113

7,220

7,097

Interest Expense, Total

-670

-546

-533

-558

-637

-646

Interest And Investment Income

94

46

43

183

385

385

Net Interest Expenses

-576

-500

-490

-375

-252

-261

Currency Exchange Gains (Loss)

-7

8

-1

-2

-41

-35

Other Non Operating Income (Expenses)

—

-34

13

7

-40

-22

-28

EBT, Excl. Unusual Items

4,140

4,983

8,720

8,696

6,905

6,773

Restructuring Charges

—

—

-509

-234

-144

-157

Merger & Related Restructuring Charges

—

—

—

—

—

—

—

—

—

19

Gain (Loss) On Sale Of Investments

—

—

-115

—

-45

-39

-39

Gain (Loss) On Sale Of Assets

—

—

—

—

—

—

—

—

—

—

Asset Writedown

—

—

—

—

—

—

—

—

-111

-100

-100

Legal Settlements

—

—

—

—

—

—

100

—

—

—

—

Other Unusual Items

—

—

-63

—

—

—

42

42

EBT, Incl. Unusual Items

4,077

4,968

8,211

8,306

6,664

6,538

Income Tax Expense

390

497

1,140

1,373

941

908

Earnings From Continuing Operations

3,687

4,471

7,071

6,933

5,723

5,630

Earnings Of Discontinued Operations

—

24

—

—

—

—

Net Income

3,687

4,495

7,071

6,933

5,723

5,630

Preferred Dividend and Other Adjustments

21

22

29

28

22

22

Net Income to Common Incl Extra Items

3,666

4,473

7,042

6,905

5,701

5,608

Net Income to Common Excl. Extra Items

3,666

4,449

7,042

6,905

5,701

5,608

Total Shares Outstanding

1,762.5

1,771.2

1,764.1

1,737.8

1,734.1

1,750

Weighted Avg. Shares Outstanding

1,768

1,773

1,775

1,753

1,740

1,739.5

Weighted Avg. Shares Outstanding Dil

1,781

1,786

1,789

1,764

1,749

1,748.5

EPS

2.1

2.5

4

3.9

3.3

3.2

EPS Diluted

2.1

2.5

3.9

3.9

3.3

3.2

EBITDA

7,771

8,789

12,742

12,380

10,463

10,344.8

Effective Tax Rate

9.6%

10%

13.9%

16.5%

14.1%

13.9%